echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The profit of bio similar medicine exceeds that of innovative medicine, and the market competition becomes increasingly fierce

    The profit of bio similar medicine exceeds that of innovative medicine, and the market competition becomes increasingly fierce

    • Last Update: 2020-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of pharmaceutical network] recently, baiaotai announced its online subscription and winning rate This means that after Zejing pharmaceutical, it has become the second company to choose the fifth set of listing standards for science and technology innovation board It is worth mentioning that on November 7 last year, the approval of the State Food and drug administration was officially passed by gelleli, a product of baiaotai, on the eve of listing, which is used to treat autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriasis It is the first adalimumab injection product developed in China with the original adalimumab as the reference drug and in accordance with the guidelines of biological similar drugs It is understood that the core patent of adamumumab expired in China in 2016, because the research and development of biological similar drugs is lower than that of the original drugs, which has a significant price advantage At present, in addition to baiaotai, domestic enterprises, such as Xinda biology, Haizheng pharmaceutical, Fuhong Hanlin and other enterprises have also started to research and develop adamumumab biological similar drugs, and are waiting for approval In addition, according to incomplete statistics, at present, there are about 20 domestic companies that have entered the stage of ind or above, and the competition is very fierce In fact, the domestic pharmaceutical companies' preference for adalimumab biological analogues mainly comes from the booming market of biological analogues in recent years Biological similar drugs, also known as biological generic drugs, are similar to the approved biological original drugs (including vaccines, blood and blood components, somatic cells, gene therapy, tissue and recombinant therapeutic proteins, etc.) There are data showing that monoclonal antibodies have been one of the larger categories in the global biopharmaceutical market since 2013 In 2018, the global monoclonal antibody market segment accounted for 55.3% of the global bio drug market, with a compound annual growth rate of 13.2% from 2014 to 2018 According to the forecast of evaluate, in 2022, the global market size of bio similar drugs will reach 9 billion US dollars, with a compound annual growth rate of 33%, far exceeding the bio medicine market Generally speaking, compared with the chemical drugs and generic drugs, the development cycle of biological similar drugs is longer, the development is difficult, the return cycle is long, and the cost is rising The R & D of a chemical generic drug usually costs no more than 5 million dollars, 2-4 years, while the R & D of a biological similar drug needs at least 100 million dollars, 4-6 years However, compared with innovative drugs, the R & D time and investment of bio similar drugs are significantly lower than that of innovative drugs, especially bio innovative drugs It is reported that a successful molecular research and development of biological innovative drugs usually takes more than $1 billion, 12 years, significantly more than the development and investment of biological similar drugs Therefore, although the investment is high, the income brought by biological similar drugs still makes enterprises dare to take risks At present, with the acceleration of drug R & D approval process by the State Drug Administration in recent years, seven domestic monoclonal antibody varieties have been approved for marketing in China In the future, China's monoclonal antibody drug market will usher in a period of rapid development, and the market competition will become more and more fierce.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.